{"trials": {"header": ["category", "drug", "nct", "type", "locations", "comments", "prior_io_ok", "publications"], "data": [["Personalized Vaccine/Cellular Immunotherapy", "NIH TIL Personalized Cellular Immunotherapy Trial", "NCT01174121", "Im", ["Maryland"], "Personalized TIL cellular therapy.  Significant in-patient hospital stay (Bethesda, MD). Requires a tumor deemed by the trial MD to be large enough & surgically harvestable. http://cancerriot.blogspot.com/p/procedures.html", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/24812403", "https://ccr.cancer.gov/sb-faqs"]], ["Personalized Vaccine/Cellular Immunotherapy", "MDA Personalized Vaccine Trial (by invitation only) - with and without PD1", "NCT02600949", "Im", ["Texas"], "MDA Personalized Vaccine Trial (by invitation only)", 1, ["http://www.nature.com/nature/journal/v520/n7549/abs/nature14426.html"]], ["Personalized Vaccine/Cellular Immunotherapy", "Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer (ATACC) - T-Cells obtained from BLOOD", "NCT02577588", "Im", ["Germany"], "Personalized Adoptive T cell therapy.  Focus on harvesting p53-mutant reactive T-Cells obtained from BLOOD", 1, []], ["Personalized Vaccine/Cellular Immunotherapy", "AutoSynVax\u2122 Personalized Vaccine", "NCT02992977", "Im", ["Florida", " Ohio"], "From website: \"AutoSynVax is an individualized vaccine made by combining synthetic versions of each patient\u2019s own cancer antigens with heat shock protein 70 (HSP70). HSP70 is known to transport protein fragments called epitopes and to play a part in displaying them to T cells, immune cells that, when sufficiently activated, can mount a potent anti-tumor response. ...We then synthesize these neo-epitopes in the form of short peptide sequences. After linking these peptides to HSP70 in our GMP-certified manufacturing facility, we plan to administer AutoSynVax vaccine along with our QS-21 Stimulon\u00ae adjuvant to provide maximum efficacy.\"", 1, ["http://agenusbio.com/pipeline/vaccines/"]], ["Non-Personalized Vaccine/Cellular Immunotherapy", "GVAX (With CY) therapeutic vaccines + Pembrolizumab (PD1)", "NCT02981524", "Im", ["Maryland"], "GVAX (With CY) therapeutic vaccines + Pembrolizumab (PD1). Currently being tested in Pancreatic Cancer. Publication listed is PANCREATIC CANCER WITHOUT PD1 - based upon preclinical data, combination with PD1 may boost efficacy", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/25584002"]], ["Non-Personalized Vaccine/Cellular Immunotherapy", "Type-1 Polarized Dendritic Cell (\u03b1DC1) Vaccine + (Interferon-\u03b12b, Rintatolimod, and Celecoxib)", "NCT02615574", "Im", ["Pennsylvania"], "Vaccine + long list of co-therapies to help facilitate activity (but NO PD-1 inhibitor). NEED TO BE HLA-A2", 1, []], ["Non-Personalized Vaccine/Cellular Immunotherapy", "Standard of Care + Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine (aka P10S PADRE vaccine)", "NCT03003195", "Im", ["Arkansas"], "Standard of Care + Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine (aka P10S PADRE vaccine) - Carbohydrate vaccine in combo with Montanide ISA 51 VG adjuvant", 1, ["https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514369/"]], ["Non-Personalized Vaccine/Cellular Immunotherapy", "Universal Donor NK Cell Therapy in Combination With ALT803", "NCT02890758", "Im", ["Ohio"], "Dose escalation of non-HLA matched (universal donor) NK cells + ALT803 which helps them grow", 1, []], ["Non-Personalized Vaccine/Cellular Immunotherapy", "CAR-T Hepatic Artery Infusions for CEA-Expressing Liver Metastases (HITM-SURE)", "NCT02850536", "Im", ["Colorado", " Rhode Island"], "CAR-T Hepatic Artery Infusions for CEA-Expressing Liver Metastases (HITM-SURE).  SEE PUBLICATION LINK for anecdotal discussion of previous clinical trial ", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/25850950", "http://coloncancersupport.colonclub.com/viewtopic.php?f=1&t=56625"]], ["Non-Personalized Vaccine/Cellular Immunotherapy", "anti-Human telomerase reverse transcriptase (hTERT) peptides vaccine", "United Kingdom Trial", "Im", ["United Kingdom"], "anti-Human telomerase reverse transcriptase (hTERT) vaccine.  A tumor associated antigen which has been studied for many years", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/18767939"]], ["Non-Personalized Vaccine/Cellular Immunotherapy", "anti-HER2 vaccine", "NCT01376505", "Im", ["Ohio"], "anti-HER2 vaccine. HER2 over-expession not an inclusin requirement but scientifically might be advantageous.  ", 1, []], ["Non-Personalized Vaccine/Cellular Immunotherapy", "OncoVax + Surgery", "NCT02448173", "Im", ["Florida + more pending"], "FOR STAGE II CRC Patients! RANDOMIZED PHASE 3 TRIAL!  Will compare surgical standard of care vs. surgery + Oncovax on recurrence rates.  Will eventually be many sites.", 1, ["http://www.vaccinogeninc.com/oncovax/oncovax-cancer-vaccine-clinical-results"]], ["PD(L)1 Combo Trials", "Atezo + Cobimitinib", "NCT02788279", "Im", ["California", " Colorado", " Connecticut", " District of Columbia", " Florida", " Illinois", " Massachusetts", " Minnesota", " Missouri", " New York", " Oklahoma", " Pennsylvania", " Tennessee", " Texas", " Washington", " Australia", " Belgium", " Canada", " France", " Germany", " Hong Kong", " Italy", " Korea", " Poland", " Spain", " United Kingdom"], "Phase 3 randomized: Stivarga vs. PDL1 vs. PDL1+MEKi. NOTE 12/2016 - TRIAL MAY BE FULL (Waiting for confirmation) ", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/26944201"]], ["PD(L)1 Combo Trials", "Atezo + Cobimitinib + Avastin", "NCT02876224", "Im", ["Colorado", " Tennessee"], "Phase 1 Trial guarenteeing Atezo+Cobi (adding in Avastin)", 0, ["http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322048/", "http://www.ncbi.nlm.nih.gov/pubmed/21358206"]], ["PD(L)1 Combo Trials", "Nivolumab (PD1) + Ipilimumab (CTLA-4) + Cobimetinib", "NCT02060188", "Im", ["Arizona", " California", " Georgia", " Massachusetts", " Minnesota", " North Carolina", " Oregon", " Pennsylvania", " Tennessee", " Texas", " Australia", " Belgium", " Canada", " France", " Ireland", " Italy", " Spain"], "Phase 2 Trial guarenteeing dosing of a PD1 inhibitor + CTLA-4 inhibitor + Cobi", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/26944201"]], ["PD(L)1 Combo Trials", "Selumetinib (MEK inhibitor) + MEDI4736 (durvalumab; PDL1 inhibitor)", "NCT02586987", "Im", ["Illinois", " Massachusettes", " New Jersey", " North Carolina"], "Phase 1 trial, everyone gets combo. MEK inhibitors complicated - different classes may theoretically behave differently in the Clinic.", 0, []], ["PD(L)1 Combo Trials", "RO6958688 + PDL1", "NCT02650713", "Im", ["California", " Connecticut", " Massachusetts", " New York", " North Carolina", " France", " Netherlands", " Spain"], "Membrane Bound CEA-CD3 Bifunctional + PDL1 combo", 1, ["http://clincancerres.aacrjournals.org/content/clincanres/early/2016/02/09/1078-0432.CCR-15-1696.full.pdf", "http://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1203498"]], ["PD(L)1 Combo Trials", "NHS-IL12 + PDL1", "NCT02994953", "Im", ["Maryland", " Massachusetts "], "NCI Trial; NHS-IL12 (modified IL12 to improve safety; T-Cell Stimulant) + PDL1 combo", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/24681847"]], ["PD(L)1 Combo Trials", "IL12 + PD1", "NCT03030378", "Im", ["Pennsylvania"], "Similar to NCT02994953 except for the form of IL12 used", 0, []], ["PD(L)1 Combo Trials", "DS-8273a + PD1", "NCT02991196", "Im", ["District of Columbia", " Texas"], "Combination of DS-8273a (agonistic TRAIL-R2 antibody) with PD1 inhibitor. Myeloid-derived suppressor cells (MDSC) one of the major contributors to immune suppression in cancer. DS-8273a has been shown clinically to reduce MDSC in cancer patients in a monotherapy Phase 1 trial", 0, ["https://www.ncbi.nlm.nih.gov/pubmed/27965309", "https://drive.google.com/file/d/0Bwc5kiYeCOflV0Nlb20xOHl1U2M/view"]], ["PD(L)1 Combo Trials", "Varlilumab + PD1", "NCT02335918", "Im", ["California", " Connecticut", " District of Columbia", " Florida", " Georgia", " Michigan", " New York", " Oregon"], "CD27 + PD1. Stimulates T-Cells. Synergistic with PD1 in animal models. Stable disease in CRC patient.", 0, ["http://www.celldex.com/docs/ASCOPoster2014finalversion_Solid-Tumors.pdf"]], ["PD(L)1 Combo Trials", "AM0010 + \u2026\u2026\u2026.", "NCT02009449", "Im", ["California", " Colorado", " Florida", " Massachusetts", " New York", " Oklahoma", " Tennessee", " Texas"], "PEGylted IL-10. Complicated multi-arm trial with multiple combination partners including PD1. Hints of CRC activity with monotherapy.  ", 1, ["http://www.armobio.com/pdf/Papadopoulos-ASCO-2016-poster-AM0010-PDAC-CRC.pdf", "http://jco.ascopubs.org/content/early/2016/08/10/JCO.2016.68.1106.abstract"]], ["PD(L)1 Combo Trials", "CC-486 + Romidepsin + PD1", "NCT02512172", "Im", ["Maryland"], "Johns Hopkins; 2 epigentic drugs to prime MSS CRC tumors for PD1 activity. A MSS-CRC specific trial", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/25071169"]], ["PD(L)1 Combo Trials", "Mocetinostat + PDL1", "NCT02805660", "Im", ["Texas"], "Epigenetic modifier (HDACi) to prime tumors to become sensitive to PD1. Simpler form of Johns Hopkins trial Mechanism of Action (NCT02512172) - allows prior PD1", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/25071169"]], ["PD(L)1 Combo Trials", "Azacitidine + PDL1", "NCT02811497", "Im", ["Canada"], "Epigenetic modifier to prime tumors to become sensitive to PD1. Simpler form of Johns Hopkins trial Mechanism of Action (NCT02512172) - CANADIAN trial. Specific arm for MSS CRC", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/25071169"]], ["PD(L)1 Combo Trials", "PD1 + Epacadostat ", "NCT02327078", "Im", ["Alabama", " California", " Colorado", " Kansas", " Maryland", " Massachusetts", " New York", " North Carolina", " North Dakota", " Pennsylvania", " South Dakota", " Tennessee", " Texas", " Utah", " Wisconsin "], "IDO1 inhibitor + PD1", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/26297050", "http://www.ncbi.nlm.nih.gov/pubmed/22108515"]], ["PD(L)1 Combo Trials", "PD1 + BMS-986205 (IDO1)", "NCT02658890", "Im", ["Arizona", " California", " Georgia", " Illinois", " Missouri", " New Jersey", " Ohio", " Pennsylvania", " Australia", " Canada", " France", " Germany", " Spain", " "], "IDO1 inhibitor + PD1", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/26297050", "http://www.ncbi.nlm.nih.gov/pubmed/22108515"]], ["PD(L)1 Combo Trials", "PD1 + Epacadostat + Azacitidine", "NCT02959437", "Im", ["Pending", " California (City of Hope)", " Illinois (U. of Chicago)"], "Epigenetic inhibitor + IDO1 inhibitor + PD1. Specific arm for MSS CRC. Epigenetic modifier to prime tumors to become sensitive to PD1", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/25071169", "http://www.ncbi.nlm.nih.gov/pubmed/26297050"]], ["PD(L)1 Combo Trials", "MEDI9447 alone or + MEDI4736 (PD1)", "NCT02503774", "Im", ["Australia California", " Connecticut", " Missouri", " North Carolina", " Ohio", " Tennessee", " Australia"], "1:1 randomization CD73 alone or + PD1", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/23983257", "http://www.ncbi.nlm.nih.gov/pubmed/21292811"]], ["PD(L)1 Combo Trials", "FPA008 alone or + PD1", "NCT02526017", "Im", ["Arizona", " Michigan", " Texas"], "anti-CSF1R alone or + PD1.  Multiple anti-CSF1R companies are specifically including MSS-CRC in their Phase 1 trial arms. Reduce Immunosuppresive Tumor Associated Macrophages.", 1, []], ["PD(L)1 Combo Trials", "AMG820 alone or + PD1", "NCT02713529", "Im", ["Texas", " Canada"], "Multiple anti-CSF1R companies are specifically including MSS-CRC in their Phase 1 trial arms.  Reduce Immunosuppresive Tumor Associated Macrophages.", 1, []], ["PD(L)1 Combo Trials", "ARRY-382 + PD1", "NCT02880371", "Im", ["Indiana", " Tennessee", " Utah"], "Multiple anti-CSF1R companies are specifically including MSS-CRC in their Phase 1 trial arms.  This agent (without PD1) had a responding Rectal cancer patient in their single drug Phase 1 trial. Can simply refuse standard therapy - don't need to have failed. Reduce Immunosuppresive Tumor Associated Macrophages.", 0, []], ["PD(L)1 Combo Trials", "PEXIDARTINIB (anti-CSF1R) + PDL1", "NCT02777710", "Im", ["France"], "Multiple anti-CSF1R companies are specifically including MSS-CRC in their Phase 1 trial arms.  Reduce Immunosuppresive Tumor Associated Macrophages.", 0, []], ["PD(L)1 Combo Trials", "LY3022855 (anti-CSF1R) + EITHER Durvalumab (PDL1) OR Tremelimumab (CTLA-4)", "NCT02718911", "Im", ["Colorado", " Florida", " Georgia", " New York", " Tennessee", " Belgium", " Czech Republic", " France", " Germany", " Israel", " Italy"], "Multiple anti-CSF1R companies are specifically including MSS-CRC in their Phase 1 trial arms.  Reduce Immunosuppresive Tumor Associated Macrophages. This is the first trial to directly compare (PD1 + anti-CSF1R) vs. (CTLA-4 + anti-CSF1R)", 1, []], ["PD(L)1 Combo Trials", "MK-8353 (formerly SCH 900353) + PD1", "NCT02972034", "Im", ["Michigan"], "PD1 + ERK inhibitor. After dose escalation is done, they are specifically enrolling *ONLY* MSS-CRC patients. Also of note are their inclusion/exclusion criteria which are more & less restrictive than normal, depending on parameter - not a standard list so read carefully.", 0, []], ["PD(L)1 Combo Trials", "JTX-2011 +/- PD1", "NCT02904226", "Im", ["California", " Colorado", " District of Columbia", " Illinois", " Massachusetts", " Missouri", " Tennessee", " Texas", " Washington"], "ICOS agonist with/without PD1 inhibitor. High ICOS expression is correlated with better clinical outcomes in MSS CRC. From patent application (WO2016154177) - combination with PD1 inhibitor IN MOUSE CT26 CRC model gave 9/10 complete responses (\"PD1 + 37A10\" in lower right hand corned of publication #2)", 1, ["https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910717/", "https://drive.google.com/file/d/0Bwc5kiYeCOflXzhKalZWeUl4aHc/view"]], ["PD(L)1 Combo Trials", "PF-04518600 (OX-40) + PDL1", "NCT02554812", "Im", ["California", " District of Columbia", " Florida", " Georgia", " Massachusetts", " Michigan", " North Carolina", " Pennsylvania", " Tennessee", " Texas", " Washington", " Australia", " Canada", " France", " Japan", " Netherlands", " United Kingdom"], "Combo of PDL1 + an OX-40 agonist (PF-04518600) to simultaneously \"release the brakes\" and \"hit the gas pedal\"", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/24586709"]], ["PD(L)1 Combo Trials", "PDL1 + Cediranib", "NCT02484404", "Im", ["Maryland"], "PDL1 + Cediranib (VEGF inhibitor) - this is the trial arm that CRC patients are shuttled into.", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/27571927", "https://www.ncbi.nlm.nih.gov/pubmed/27729297"]], ["PD(L)1 Combo Trials", "LAG525 +/- PDR001 (PD1)", "NCT02460224", "Im", ["New York", " North Carolina", " Texas", " Utah", " Australia", " Belgium", " Canada", " Hong Kong", " Italy", " Japan", " Singapore", " Spain"], "PD1 vs. PD1 + LAG3 inhibitor. LAG3 is a different checkpoint than PD1.  Dose escalation phase of trial open to MSS. Dual inhibition of two different checkpoints.", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/22186141"]], ["PD(L)1 Combo Trials", " MK-7684 +/- PD1", "NCT02964013", "Im", ["Texas", " Israel"], "TIGIT (a new checkpoint) alone or with PD1. Dual inhibition of two different checkpoints.", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/27819527", "https://www.ncbi.nlm.nih.gov/pubmed/27793572"]], ["PD(L)1 Combo Trials", "PDL1 + \"Monalizumab\" (previously IPH2201). ", "NCT02671435", "Im", ["Arizona", " Colorado", " Florida", " Maryland", " New York", " Texas"], "PDL1 + ANTI-NKG2A.  Monalizumab is unique in that it not only attracts T-Cells but also Natural Killer (NK) Cells into action. ", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/21953582", "http://innate-pharma.com/sites/default/files/ncic_clinical_trials_group_-_tat_meeting_2015.pdf"]], ["PD(L)1 Combo Trials", "CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) ", "NCT02812875", "Im", ["California", " Colorado", " Florida", " North Carolina", " Pennsylvania", " Tennessee"], "ORAL Antagonist against (3) Checkpoints: PDL1, PDL2 and VISTA", 1, ["http://www.curis.com/pipeline/ca-170"]], ["PD(L)1 Combo Trials", "PD1 + MK-1454 (STING agonist)", "NCT03010176", "Im", ["New York", " Israel"], "PD1 + STING agonist (innate immune system inhibitor).  IMPORTANT: Needs a tumor that is accessible for easy direct injection of STING agonist (e.g. just below skin)", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/27821498", "https://drive.google.com/file/d/0Bwc5kiYeCOflRUR5MHplZFVBV00/view"]], ["PD(L)1 Combo Trials", "durvalumab (MEDI4736, PDL1) + [AZD9150 (STAT3 inhibitor)] OR [AZD5069 (CXCR2 antagonist)] ", "NCT02499328", "Im", ["Alabama", " California", " Colorado", " Florida", " Indiana", " Massachusetts", " Michigan", " Montana", " New Jersey", " Ohio", " Pennsylvania", " Tennessee", " Texas", " Virginia", " Washington", " Belgium", " Canada", " Germany", " Italy", " Spain", " United Kingdom"], "PDL1 + Either a STAT3 inhibitor or a CXCR2 antagonist.  MSS-CRC elegible during the initial phases of the trial.  Side note: inclusion criteria includes higher allowed levels of bilirubin, ALT, and AST for those with liver mets", 0, ["https://www.ncbi.nlm.nih.gov/pubmed/27678219", "https://www.ncbi.nlm.nih.gov/pubmed/27265504"]], ["PD(L)1 Combo Trials", "AZD1775 (WEE1 inhibitor) + Durvalumab (MEDI4736, PDL1) ", "NCT02617277", "Im", ["Colorado", " Florida", " Tennessee"], "AZD1775 (WEE1 inhibitor) + Durvalumab (MEDI4736, PDL1)", 1, []], ["PD(L)1 Combo Trials", "PD1 + CTLA4 + FOLFOX", "NCT02754856", "Im", ["Texas"], "ONLY in Liver resectable met patients.  Meant to improve odds of no recurrence after CRC liver resection", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/27496709", "https://www.google.com/patents/WO2013181452A1?cl=en"]], ["PD(L)1 Combo Trials", "Erbitux/Cetuximab + PD1", "NCT02713373", "Im", ["New York "], "EGFR inhibitor + PD1. Can not have had Erbitux/cetuximab before.  Need to be KRAS wildtype (i.e. non-mutated)", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/27597284"]], ["PD(L)1 Combo Trials", "PD1 + FOLFIRI", "NCT02423954", "Im", ["Arizona "], "Either Irinotecan + PD1 or XELIRI+ PD1 in patients who had not previously had irinotecan", 1, []], ["PD(L)1 Combo Trials", "Xeloda + Avastin +/- PDL1", "NCT02873195", "Im", ["Minnesota"], "Randomized.  PD1 alone gives 10% stable disease in MSS-CRC patients.  Adding it to standard of care to see if activity increases compared to Standard of care alone.", 0, []], ["PD(L)1 Combo Trials", "TAS-102 (Lonsurf) + PD1", "NCT02860546", "Im", ["Colorado", " Florida", " Tennessee"], "Combo treatment of TAS-102 (Lonsurf) and PD1.  No prior treatment of either TAS0-102 or PD1 allowed.", 0, []], ["PD(L)1 Combo Trials", "RRx-001 + PD1", "NCT02518958", "Im ", ["Walter Reed Military Hosp. in Maryland"], "Phase 1 Combo with PD1", 0, ["None for this dose combination"]], ["PD(L)1 Combo Trials", "PD-1 + Poly-ICLC", "NCT02834052", "Im", ["Georgia"], "Innate immune system activator (TLR agonist) to make Cold MSS tumors hot towards PD-1 inhibition", 0, ["https://www.ncbi.nlm.nih.gov/pubmed/?term=25281915"]], ["PD(L)1 Combo Trials", "MEDI4736 (PD1) + Tremelimumab (CTLA4)", "NCT02261220", "Im", ["Arizona", " California", " Colorado", " Connecticut", " Florida", " Georgia", " Illinois", " Kentucky", " Michigan", " Minnesota", " Missouri", " New York", " Ohio", " Oregon", " Pennsylvania", " South Carolina", " Texas", " Virginia", " Washington", " Canada", " France", " Israel", " Korea", " Netherlands", " Spain", " United Kingdom"], "Preliminary data for MSS-CRC on the combo of PD-1+CTLA-4 inhibitors (but different drugs than these) was released at ASCO-2016 - preliminary data did not show activity. ", 1, []], ["PD(L)1 Combo Trials", "Atezo (PDL1) + Avastin in \"MSI-LIKE\" tumors (see comments)", "NCT02982694", "Im", ["Belgium", " Italy", " Netherlands", " Spain"], "PDL1 + Avastin in MSS tumors which are \"MSI-LIKE\" tumor as determined by a proprietary test", 0, []], ["Immune Activating Bifunctional Drugs", "RO6895882 + Atezo", "NCT02350673", "Im", ["Connecticut", " New York", " Denmark", " Netherlands", " Spain", " Switzerland"], "CEA-IL2 bifunctional +PD-L1. CEA-IL2 bifunctional to make a cold tumor hot", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/26861458"]], ["Immune Activating Bifunctional Drugs", "RO6958688", "NCT02324257", "Im", ["Connecticut", " Massachusetts", " Netherlands", " Spain", " "], "CEA-CD3 bifunctional to make a cold tumor hot  ", 1, ["http://clincancerres.aacrjournals.org/content/clincanres/early/2016/02/09/1078-0432.CCR-15-1696.full.pdf"]], ["Immune Activating Bifunctional Drugs", "MSB0011359C (M7824)", "NCT02517398", "Im", ["Arizona", " California", " Colorado", " Connecticut", " Florida", " Georgia", " Illinois", " Louisiana", "  Maryland", " Massachusetts", " Michigan", " Missouri", " Nevada", " North Carolina", " Ohio", " Pennsylvania", " South Carolina", " Tennessee", " Texas", " Virginia", " Washington", " Australia", " Belgium", " Canada", " France", " Italy", " Korea", " Spain", " Taiwan"], "PD-L1 and TGF-\u03b2 trap  bifunctional.  In preliminary data, showed partial response in pancreatic cancer patient. TGF-beta clearly plays an important role in color rectal cancer. Not only does it seem to drive tumor progression, but it also inhibits effector function. In fact high TGF-beta levels produced by Ras mutated call rectal cancer tumors have been demonstrated in vitro to convert effector T cells into regulatory T cells.", 1, ["http://www.ejcancer.com/article/S0959-8049(16)32906-9/abstract", "https://www.ncbi.nlm.nih.gov/m/pubmed/26880715/"]], ["Immune Activating Bifunctional Drugs", "MGD007", "NCT02248805", "Im", ["Maryland", " Massachusetts", " North Carolina", " Oregon"], "gpA33xCD3 Bifunctional to make a cold tumor hot.  In triweekly dosing dose expansion phase for MSS CRC", 1, ["http://files.shareholder.com/downloads/AMDA-278VRP/2815900939x0x755676/91E234E8-6C0A-4693-8923-9EF18DC0CE8D/MacroGenics%202014%20AACR%20MGD007%20Poster%20-%20FINAL.PDF"]], ["Immune Activating Bifunctional Drugs", "PF-06671008", "NCT02659631", "Im", ["New York", " Texas", " Utah"], "Specifically targetting MSS-CRC. P-cadherinxCD3 bifunctional to make a cold tumor hot", 1, ["http://cancerres.aacrjournals.org/content/75/15_Supplement/2476.abstract?cited-by=yes&legid=canres;75/15_Supplement/2476", "http://www.mdpi.com/2073-4468/5/1/6"]], ["Non-PD1 Immunotherapy Drugs", "Hu5F9-G4", "NCT02953782", "Im", ["Michigan", " Tennessee", " Texas"], "anti-CD47 + cetuximab.  Innate immune system activator prompting macrophage attack of tumors. MSS-CRC is lead solid tumor indication.", 1, ["http://www.pnas.org/content/109/17/6662.long", "http://www.tandfonline.com/doi/full/10.1080/19420862.2015.1011450"]], ["Non-PD1 Immunotherapy Drugs", "NHS-IL12", "NCT01417546", "Im", ["Maryland"], "NCI Trial; NHS-IL12 (modified IL12 to improve safety; T-Cell Stimulant) ", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/24681847"]], ["Non-PD1 Immunotherapy Drugs", "Recombinant Human hetIL-15 ", "NCT02452268", "Im", ["Maryland"], "NCI Trial; T-Cell stimulant", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/26719339"]], ["Non-PD1 Immunotherapy Drugs", "CB-1158 ", "NCT02903914", "Im", ["Texas"], "\"arginase inhibitor\" named \"CB-1158\". Arginase is immunosupressive and it has been known for years to be a clinical marker for CRC - so they are specifically recruiting MSS-CRC patients for an arm of the trial.  Initial testing is monotherapy for CRC", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/1643605", "https://www.ncbi.nlm.nih.gov/pubmed/12115381"]], ["Non-PD1 Immunotherapy Drugs", "JNJ-61610588", "NCT02671955", "Im", ["New York", " North Carolina", " Pennsylvania", " Tennessee", " Texas - All sites have suspended patient recruitment for now"], "anti-VISTA checkpoint inhibitor. Specifically mention CRC", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/24894088", "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22US+20140341920%22&OS=%22US+20140341920%22&RS=%22US+20140341920%22"]], ["Non-PD1 Immunotherapy Drugs", "MBN1703", "NCT02077868", "Im", ["Austria", " Belgium", " Estonia", " France", " Germany", " Italy", " Spain", " United Kingdom", " "], "MBN1703 (TLR agonist following chemotherapy induction therapy)", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/24816725 "]], ["Non-PD1 Immunotherapy Drugs", "Ipilimumab + MGN1703 ", "NCT02668770", "Im", ["Texas"], "CTLA-4 immunotherapy + an iv-dosed TLR agonist which activates the innate immune system", 1, ["MGN1703 alone: http://www.ncbi.nlm.nih.gov/pubmed/24816725 "]], ["Oncolytic Virus", "\"Enadenotucirev\" Oncolytic virus + PD1", "NCT02636036", "Im", ["Arizona", " Indiana", " Michigan", " California"], "Oncolytic virus + PD1. Specifically mention CRC.", 0, ["http://www.psioxus.com/downloads/2014-09ESMO2014Poster1064pEVOLVE.pdf", "http://www.psioxus.com/psioxus-products-enadenotucirev-more.asp"]], ["Oncolytic Virus", "Oncolytic virus", "NCT02285816", "Im", ["Canada"], "Oncolytic virus with required MAGE-A3 expression (test done by trial)", 1, []], ["Oncolytic Virus", "\"REOLYSIN\u00ae\" Oncolytic virus + FOLFIRI + Bev", "NCT01274624", "Im", ["New York"], "Oncolytic virus + FOLFIRI + Bev. EXCLUDED if previously had FOLFIRI - met to be a replacement therapy instead of standard FOLFIRI", 1, []], ["Oncolytic Virus", "\"ONCOS-102\" Oncolytic virus + PDL1", "NCT02963831", "Im", ["New York"], "Oncolytic virus + PDL1. Subjects with PERITONEAL DISEASE who have failed prior standard chemotherapy", 0, []], ["Oncolytic Virus", "\"T-Vec\" Oncolytic virus + PD1", "NCT02978625", "Im", ["New Jersey"], "Oncolytic virus + PD1 for SIGNET RING CELL CARCINOMA ", 1, []], ["Radiation in situ vaccination + PD1", "PD1 + SBRT", "NCT02608385", "Im", ["Illinois"], "PD1 blockage in combination with SBRT (radiation) attempting to make cold tumors hot via immunogenic cell death & abscopal effect.", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/25701325"]], ["Radiation in situ vaccination + PD1", "PD1 + SBRT (Liver mets only)", "NCT02837263", "Im", ["Wisconsin"], "NEED LIVER METS.  PD1 blockage in combination with SBRT (radiation) attempting to make cold tumors hot via immunogenic cell death & abscopal effect.", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/25701325"]], ["Radiation in situ vaccination + PD1", "PD1 + SBRT", "NCT02437071", "Im", ["New York"], "PD1 blockage in combination with SBRT (radiation) attempting to make cold tumors hot via immunogenic cell death & abscopal effect.", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/25701325"]], ["Radiation in situ vaccination + PD1", "PD1 + SBRT", "NCT02886585", "Im", ["Massachusetts"], "SPECIFICALLY for patients WITH BRAIN METS.  Open to BOTH MSS and MSI-high. PD1 blockage in combination with SBRT (radiation) attempting to make cold tumors hot via immunogenic cell death & abscopal effect.", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/25701325"]], ["Radiation in situ vaccination + PD1", "PD1 + CTLA4 +/- SBRT", "NCT02888743", "Im", ["Massachusetts"], "MSS-CRC only. 3-arm.  Every patient get PDL1 + CTLA (Cohort 1), Cohorts 2-3 get the same drugs but different levels of irradiation. Irradiated met needs to be in LIVER. Checkpoint blockage in combination with SBRT (radiation) attempting to make cold tumors hot via immunogenic cell death & abscopal effect.", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/25701325"]], ["Radiation in situ vaccination + PD1", "Durvalumab (PDL1) + Tremelimumab (CTLA-4) following palliative radiotherapy", "NCT03007407", "Im", ["Pending"], "Durvalumab (PDL1) + Tremelimumab (CTLA-4) following palliative radiotherapy. ", 0, ["http://www.ncbi.nlm.nih.gov/pubmed/25701325"]], ["Ablation In Situ Vaccination with or without PD1", "Durvalumab (MEDI4736, PDL1) + Tremelimumab (CTLA-4) following MSS-CRC Radioembolization in the Liver", "NCT03005002", "Im", ["California"], "Durvalumab (MEDI4736, PDL1) + Tremelimumab (CTLA-4) following MSS-CRC Radioembolization in the Liver", 0, ["https://www.ncbi.nlm.nih.gov/pubmed/26933175"]], ["Ablation In Situ Vaccination with or without PD1", "AlloStim + Cryoablation", "NCT02380443", "Im", ["Arizona"], "CRC specific study.  Goal to activate the immune system with AlloStim and then release personalized neoantigens via cryoablation.", 1, ["http://www.immunovative.com/news/news/cryovax%C2%AE-next-generation-immunotherapy-for-metastatic-colorectal-cancer-mcrc-begins-usa-phase-iib-clinical-trial"]], ["Treading Water Phase 2-3", "BBI608 + \u2026.. (including PD1)", "Multiple - see clinicaltrials .gov hyperlink", "Im OR Tw", ["Alabama ", " Arizona", " Colorado", " Florida", " Georgia", " Illinois", " Indiana", " Massachusetts", " Minnesota", "  Nebraska", " New Jersey", " New York", " North Carolina", " Ohio", " Oregon", " Pennsylvania", " South Carolina", " Tennessee", " Texas", " Virginia", " Washington", " Canada", " Japan"], "Significant preliminary activity seen in heavily pre-treated patients.  Appears to resensitize resistant patients to FOLFIRI", 0, ["http://www.bostonbiomedical.com/wp-content/uploads/Abst569-BBI608-246-ASCOGI2016.pdf"]], ["Treading Water Phase 2-3", "RRx-001 + Irinotecan (Sequential)", "NCT02096354", "Tw", ["California", " Maryland"], "Randomized 2:1 with Stivarga.  Need to be irinotecan resistent, no prior Stivarga", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/26296952", "http://tatcongress.org/wp-content/uploads/2015/03/O3.8-Corey-Carter.pdf "]], ["Treading Water Phase 2-3", "RRx-001 + Irinotecan (Simultaneous)", "NCT02801097", "Tw", ["California", " New Jersey"], "Phase 1 UC-Davis and NJ sites; different dose schedule from Phase 2 sites: Simultaneous dosing of RRx-001 with irinotecan. Need to be irinotecan resistent", 1, ["None for this dose schedule"]], ["Treading Water Phase 2-3", "Xilonix (aka MABp1)", "NCT01767857", "Tw", ["Arizona", " California", " Colorado", " Florida", " Georgia", " Michigan", " New Mexico", " New York", " Ohio", " Oregon", " Pennsylvania", " Tennessee", " Texas", " Virginia", " Washington"], "Phase 2 data promising, European Phase 3 data inconclusive, low side effect, designed to improve quality of life in addition to potentially anti-cancer activity. Randomized Phase 3 trial", 1, ["http://www.ncbi.nlm.nih.gov/pubmed/24746841"]], ["Treading Water Phase 2-3", "BBI-503 (aka Amcasertib)", "Multiple - see clinicaltrials .gov hyperlink", "Tw", ["California", " Colorado", " Illinois", " Indiana", " Louisiana", " Massachusetts", " New York", " Nevada", " Texas", " Virginia", " Washington", " Canada"], "\"Stemness\" kinase inhibitor.  Designed to attack CRC cells with \"stem cell properties\".  \"Nanog\" is a biomarker for CRC cells with \"stem cell properties\". Preliminary data shows that CRC with Nanog expression is more likely to respond to BBI-503 treatment. Testing for Nanog expression is not a standard test but would be done by the clinical trial.", 1, ["http://meetinglibrary.asco.org/content/135094-144", "http://meetinglibrary.asco.org/content/153416-156"]], ["Treading Water Phase 2-3", "IMMU-132 (anti-Trop-2 ADC)", "NCT01631552", "Tw", ["Colorado", " Connecticut", " Delaware", " Florida", " Indiana", " Massachusetts", " New York", " Tennessee", " Texas", " Washington"], "IMMU-132 (anti-Trop-2 ADC). CRC Partial Response seen in Phase 1 Trial", 1, ["http://clincancerres.aacrjournals.org/content/21/17/3870.long"]], ["Treading Water Phase 2-3", "Chemo +/- Theraspheres (y90)", "NCT01483027", "Tw", ["California", " District of Columbia", " Florida", " Illinois", " Indiana", " Kentucky", " Maryland", " Massachusetts", " Michigan", " Minnesota", " Missouri", " New York", " Ohio", " Pennsylvania", " Texas", " Pennsylvania", " Texas", " Utah", " Virginia", " Washington", " Wisconsin", " Austria", " Belgium", " Canada", " China", " Czech Republic", " France", " Italy", " Korea", " Singapore", " Spain", " United Kingdom", " "], "RANDOMIZED PHASE 3 TRIAL FOR LIVER METS; Standard of Care Chemo =/- Theraspheres (y90); Primary tumor NOT resected but clinically stable; Tumor replacement <50% of total liver volume; Failed first line chemo - HAVE NOT STARTED 2nd LINE CHEMO YET!", 1, ["https://www.ncbi.nlm.nih.gov/pubmed/25795047", "https://www.ncbi.nlm.nih.gov/pubmed/23777743"]], ["Treading Water Phase 2-3", "Encorafenib + Cetuximab +/- Binimetinib vs. Irinotecan/Cetuximab or FOLFIRI/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)", "NCT02928224", "Tw", ["California", " Colorado", " Connecticut", " Washington", " Netherlands"], "Randomized Phase 3 trial for BRaF V600E MUTANT CRC.  BRAF + EGFR inhibitor +/- MEK inhibitor versus FOLFIRI+EGFR inhibitor", 1, []], ["Treading Water Phase 2-3", "TRC102 + Temozolomide", "NCT01851369", "Tw", ["Maryland"], "Confirmed objective response in a CRC patient (see Literature hyperlink for details)", 1, ["http://www.traconpharma.com/pdfs/TRC102_TMZ_ASCO_2016_Poster.pdf"]]]}, "created_at": 1489091075.586083}